A population physiologically-based pharmacokinetic model to characterize antibody disposition in pediatrics and evaluation of the model using infliximab.

Hsuan Ping ChangValentina ShakhnovichAdam FrymoyerRyan Sol FunkMara L BeckerK T ParkDhaval K Shah

Published in: British journal of clinical pharmacology (2021)

The paediatric PBPK model presented here can serve as a framework to characterize the PK of antibodies in paediatric patients. The model can also be applied to other protein therapeutics to advance precision medicine paradigm and optimize antibody dosing regimens in children.

Keyphrases

emergency department
intensive care unit
newly diagnosed
small molecule
prognostic factors
binding protein
protein protein
ulcerative colitis